Neumora Therapeutics (NASDAQ:NMRA) Shares Up 5.8%

Neumora Therapeutics, Inc. (NASDAQ:NMRA) rose 5.8% during trading on Friday . The stock traded as high as $9.36 and last traded at $9.36. Approximately 212,704 shares were traded during mid-day trading, a decline of 56% from the average daily volume of 483,748 shares. The stock had previously closed at $8.85.

Analyst Ratings Changes

NMRA has been the subject of several analyst reports. Royal Bank of Canada restated an “outperform” rating and issued a $31.00 target price on shares of Neumora Therapeutics in a research note on Thursday, March 28th. JPMorgan Chase & Co. raised their target price on Neumora Therapeutics from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Monday, March 18th. Finally, William Blair restated an “outperform” rating on shares of Neumora Therapeutics in a research note on Friday, April 12th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Neumora Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $22.57.

Neumora Therapeutics Trading Up 5.9 %

The stock has a 50-day moving average price of $9.76 and a 200-day moving average price of $13.60.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.34). On average, sell-side analysts forecast that Neumora Therapeutics, Inc. will post -1.46 earnings per share for the current year.

Institutional Trading of Neumora Therapeutics

Hedge funds have recently bought and sold shares of the company. Amalgamated Bank bought a new stake in Neumora Therapeutics in the 4th quarter worth approximately $29,000. Tower Research Capital LLC TRC bought a new stake in Neumora Therapeutics in the 4th quarter worth approximately $44,000. Strs Ohio bought a new stake in Neumora Therapeutics in the 4th quarter worth approximately $54,000. SG Americas Securities LLC bought a new stake in Neumora Therapeutics in the 4th quarter worth approximately $108,000. Finally, New York State Common Retirement Fund bought a new stake in Neumora Therapeutics in the 4th quarter worth approximately $118,000. Institutional investors own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.